Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410479 | 0.89 | CHRNB2 (0.54) | CHRNB2CHRNA4 | |
| SCHEMBL15539927 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL15538842 | 0.80 | CHRNB2 (0.53) | CHRNB2CHRNA4 | |
| SCHEMBL23530012 | 0.79 | PIM1 (0.38) | ATXN2DHFRDCPSPIM1CYP2D6 | |
| SCHEMBL25434662 | 0.76 | CHRNB2 (0.46) | CHRNB2CHRNA4GABRA1 | |
| SCHEMBL30618289 | 0.76 | CHRNB2 (0.46) | CHRNB2CHRNA4GABRA1 | |
| SCHEMBL4979209 | 0.75 | CHRNB2 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL31080672 | 0.74 | ATXN2 (0.41) | ATXN2DHFRDCPSPIM1CYP2D6 | |
| SCHEMBL8440186 | 0.73 | CHRNB2 (0.59) | CHRNB2CHRNA4 | |
| SCHEMBL518013 | 0.72 | BCHE (0.47) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328898-B1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI SA (FR) | 2014-12-24 | — | — | EP | disclosed |
| EP-2328898-B1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI SA (FR) | 2014-12-24 | — | — | EP | disclosed |
| US-8673917-B2 | 2-heteroaryl-pyrrolo [3,4-C]pyrrole derivatives, and use thereof as SCD inhibitors | SANOFI (FR) | 2014-03-18 | — | — | US | disclosed |
| US-8673917-B2 | 2-heteroaryl-pyrrolo [3,4-C]pyrrole derivatives, and use thereof as SCD inhibitors | SANOFI (FR) | 2014-03-18 | — | — | US | disclosed |
| US-8673917-B2 | 2-heteroaryl-pyrrolo [3,4-C]pyrrole derivatives, and use thereof as SCD inhibitors | SANOFI (FR) | 2014-03-18 | — | — | US | disclosed |
| US-20120028986-A1 | 2-HETEROARYL-PYRROLO [3,4-C]PYRROLE DERIVATIVES, AND USE THEREOF AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2012-02-02 | — | — | US | disclosed |
| US-20120028986-A1 | 2-HETEROARYL-PYRROLO [3,4-C]PYRROLE DERIVATIVES, AND USE THEREOF AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2012-02-02 | — | — | US | disclosed |
| US-20120028986-A1 | 2-HETEROARYL-PYRROLO [3,4-C]PYRROLE DERIVATIVES, AND USE THEREOF AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2012-02-02 | — | — | US | disclosed |
| EP-2328898-A1 | 2-HETEROARYL-PYRROLO [3, 4-C]PYRROLE DERIVATIVES AND THE USE THEREOF AS SCD INHIBITORS | Sanofi-aventis (FR) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010028761-A1 | 2-HETEROARYL-PYRROLO [3, 4-C]PYRROLE DERIVATIVES AND THE USE THEREOF AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010028761-A1 | 2-HETEROARYL-PYRROLO [3, 4-C]PYRROLE DERIVATIVES AND THE USE THEREOF AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028986-A1 | 2-HETEROARYL-PYRROLO [3,4-C]PYRROLE DERIVATIVES, AND USE THEREOF AS SCD INHIBITORS | SCD, SCD5, PC | CHRNB2 4870/4885CHRNA4 4885/4885ATXN2 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.